| Year |
Citation |
Score |
| 2021 |
Nelhűbel GA, Cserepes M, Szabó B, Türk D, Kárpáti A, Kenessey I, Rásó E, Barbai T, Hegedűs Z, László V, Szokol B, Dobos J, Őrfi L, Tóvári J. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. Pathology Oncology Research : Por. 27: 620256. PMID 34257586 DOI: 10.3389/pore.2021.620256 |
0.332 |
|
| 2019 |
Baska F, Sipos A, Őrfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, Cserepes MT, Tóvári J, Garamvölgyi R, Krekó M, Őrfi L. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases. European Journal of Medicinal Chemistry. 184: 111710. PMID 31614258 DOI: 10.1016/J.Ejmech.2019.111710 |
0.353 |
|
| 2019 |
Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I. Targeted drug combination therapy design based on driver genes. Oncotarget. 10: 5255-5266. PMID 31523388 DOI: 10.18632/Oncotarget.26985 |
0.336 |
|
| 2018 |
Kenessey I, Kramer Z, István L, Cserepes MT, Garay T, Hegedűs B, Dobos J, Tímár J, Tóvári J. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. Melanoma Research. PMID 30124539 DOI: 10.1097/Cmr.0000000000000488 |
0.438 |
|
| 2018 |
Nemes Z, Takács-Novák K, Völgyi G, Valko K, Béni S, Horváth Z, Szokol B, Breza N, Dobos J, Szántai-Kis C, Illyés E, Boros S, Kok RJ, Őrfi L. Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML. Bioorganic & Medicinal Chemistry Letters. PMID 29935772 DOI: 10.1016/J.Bmcl.2018.06.026 |
0.324 |
|
| 2018 |
Czudor Z, Balogh M, Bánhegyi P, Boros S, Breza N, Dobos J, Fábián M, Horváth Z, Illyés E, Markó P, Sipos A, Szántai-Kis C, Szokol B, Őrfi L. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma. Bioorganic & Medicinal Chemistry Letters. PMID 29329658 DOI: 10.1016/J.Bmcl.2018.01.002 |
0.333 |
|
| 2017 |
Sólyomváry A, Alberti Á, Darcsi A, Könye R, Tóth G, Noszál B, Molnár-Perl I, Lorántfy L, Dobos J, Őrfi L, Béni S, Boldizsár I. Optimized conversion of antiproliferative lignans pinoresinol and epipinoresinol: Their simultaneous isolation and identification by centrifugal partition chromatography and high performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1052: 142-149. PMID 28384606 DOI: 10.1016/J.Jchromb.2017.03.036 |
0.311 |
|
| 2016 |
Kenessey I, Kói K, Horváth O, Cserepes M, Molnár D, Izsák V, Dobos J, HegedÅ S B, Tóvári J, Tímár J. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget. PMID 27780929 DOI: 10.18632/Oncotarget.12806 |
0.435 |
|
| 2016 |
Garamvölgyi R, Dobos J, Sipos A, Boros S, Illyés E, Baska F, Kékesi L, Szabadkai I, Szántai-Kis C, Kéri G, Őrfi L. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. European Journal of Medicinal Chemistry. 108: 623-43. PMID 26724730 DOI: 10.1016/J.Ejmech.2015.12.001 |
0.415 |
|
| 2015 |
Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Heged?s B. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. Pathology Oncology Research : Por. PMID 25749811 DOI: 10.1007/S12253-015-9916-9 |
0.408 |
|
| 2015 |
Garay T, Kenessey I, Molnár E, Juhász É, Réti A, László V, Rózsás A, Dobos J, Döme B, Berger W, Klepetko W, Tóvári J, Tímár J, Heged?s B. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. Plos One. 10: e0117021. PMID 25646931 DOI: 10.1371/Journal.Pone.0117021 |
0.49 |
|
| 2015 |
Kenessey I, Kói K, Cserepes M, Dobos J, Hegedűs B, Tóvári J, Tímár J. Abstract 47: KRAS-mutation dependent effect of zoledronic acid in human NSCLC preclinical models Cancer Research. 75: 47-47. DOI: 10.1158/1538-7445.Am2015-47 |
0.423 |
|
| 2013 |
Dobos J, Mohos A, Tóvári J, Rásó E, Lőrincz T, Zádori G, Tímár J, Ladányi A. Sex-dependent liver colonization of human melanoma in SCID mice--role of host defense mechanisms. Clinical & Experimental Metastasis. 30: 497-506. PMID 23203681 DOI: 10.1007/S10585-012-9554-5 |
0.639 |
|
| 2011 |
Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, Tímár J. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunology, Immunotherapy : Cii. 60: 1729-38. PMID 21779876 DOI: 10.1007/S00262-011-1071-X |
0.597 |
|
| 2011 |
Dobos J, Kenessey I, Tímár J, Ladányi A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathology Oncology Research : Por. 17: 729-34. PMID 21455635 DOI: 10.1007/S12253-011-9377-8 |
0.664 |
|
| 2010 |
Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, Hegedus B, Renyi-Vamos F, Varga J, Lorincz Z, Paku S, Ostoros G, Rozsas A, Timar J, Dome B. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1120-9. PMID 20581707 DOI: 10.1097/Jto.0B013E3181E2C1Ff |
0.46 |
|
| 2010 |
Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, et al. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Current Cancer Drug Targets. 10: 332-42. PMID 20370683 DOI: 10.2174/156800910791190184 |
0.496 |
|
| 2009 |
Dobos J. [Endocrine factors influencing melanoma progression]. Magyar Onkologia. 53: 47-50. PMID 19318326 DOI: 10.1556/MOnkol.53.2009.1.7 |
0.441 |
|
| 2009 |
Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, Ankersmit HJ, Lang G, Hoda MA, Nierlich P, Dome B. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1741-6. PMID 19240177 DOI: 10.1158/1078-0432.Ccr-08-1372 |
0.491 |
|
| 2009 |
Dome P, Teleki Z, Rihmer Z, Peter L, Dobos J, Kenessey I, Tovari J, Timar J, Paku S, Kovacs G, Dome B. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Molecular Psychiatry. 14: 523-31. PMID 18180758 DOI: 10.1038/Sj.Mp.4002138 |
0.341 |
|
| 2008 |
Lövey J, Bereczky B, Gilly R, Kenessey I, Rásó E, Simon E, Dobos J, Vágó A, Kásler M, Döme B, Tímár J, Tóvári J. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. Strahlentherapie Und Onkologie : Organ Der Deutschen RöNtgengesellschaft ... [Et Al]. 184: 1-7. PMID 18188516 DOI: 10.1007/S00066-008-1745-2 |
0.326 |
|
| 2007 |
Lövey J, Kenessey I, Rásó E, Dobos J, Vágó A, Kásler M, Futosi K, Döme B, Tímár J, Tóvári J. [Human recombinant erythropoietin-alpha increases the efficacy of irradiation in preclinical model]. Magyar Onkologia. 51: 53-61. PMID 17417676 |
0.311 |
|
| 2007 |
Tóvári J, Dobos J, Kenessey I, Ostoros G, Kovács G, Tímár J, Döme B. 6589 POSTER Level of circulating endothelial progenitor cells is a potential surrogate marker in human non-small cell lung cancer Ejc Supplements. 5: 385. DOI: 10.1016/S1359-6349(07)71417-9 |
0.444 |
|
| 2006 |
Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, Bogos K, Tovari J. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Research. 66: 7341-7. PMID 16849585 DOI: 10.1158/0008-5472.Can-05-4654 |
0.6 |
|
| 2006 |
Döme B, Rásó E, Dobos J, Mészáros L, Varga N, Puskás LG, Fehér LZ, Lörincz T, Ladányi A, Trikha M, Honn KV, Tímár J. Erratum: Parallel expression of IIb3 and v3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype (International Journal of Cancer (2005) 116 (27-35)) International Journal of Cancer. 119. DOI: 10.1002/Ijc.21830 |
0.626 |
|
| 2005 |
Döme B, Rásó E, Dobos J, Mészáros L, Varga N, Puskás LG, Fehér LZ, Fehér LZ, Lörincz T, Ladányi A, Trikha M, Honn KV, Tímár J. Parallel expression of alphaIIbbeta3 and alphavbeta3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype. International Journal of Cancer. 116: 27-35. PMID 15761867 DOI: 10.1002/Ijc.20991 |
0.654 |
|
| 2005 |
Dome B, Timar J, Ostoros G, Meszaros L, Dobos J, Raso E, Renyi-Vamos E, Bogos J, Agocs L, Tovari J. P-947 The role of circulating endothelial progenitor cells in non-smallcell lung cancer Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)81440-0 |
0.371 |
|
| 2004 |
Dobos J, Tímár J, Bocsi J, Burián Z, Nagy K, Barna G, Peták I, Ladányi A. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. International Journal of Cancer. 112: 771-6. PMID 15386380 DOI: 10.1002/Ijc.20473 |
0.651 |
|
| Show low-probability matches. |